Monitor the shareholder vote outcome on October 16, 2026. If the extension passes, watch for a business combination announcement before November 25, 2026. If it fails, expect liquidation and warrants expiring worthless. The stock trades near trust value (~$10.78 vs $10.75 redemption), limiting arbitrage.
Price Chart
Executive Summary
Oaktree Acquisition Corp. III Life Sciences (OACC) is seeking shareholder approval to extend its deadline to complete a business combination from October 25, 2026 to November 25, 2026, with the ability to further extend monthly up to May 25, 2027. The filing is a routine SPAC extension vote with redemption rights for public shareholders at ~$10.75 per share. Without approval, the SPAC will liquidate and warrants will expire worthless.
Key Facts
- Shareholder meeting scheduled for October 16, 2026 to vote on extension amendment and adjournment proposals.
- Extension would move the termination date from October 25, 2026 to November 25, 2026, with up to six additional one-month extensions possible until May 25, 2027.
- Trust account holds approximately $206,314,849 as of September 30, 2026, equating to ~$10.75 per public share redemption price.
- Sponsor (Oaktree Acquisition Holdings III LS, LLC) owns ~21.9% of outstanding ordinary shares and intends to vote FOR both proposals.
- Approval requires a two-thirds majority of votes cast; if all shares are present, ~11 million public shares (57.3% of Class A) are needed.
- Public shareholders may redeem shares at ~$10.75 regardless of vote, with redemption deadline October 14, 2026.
- If extension fails and no business combination by October 25, 2026, OACC will liquidate and warrants expire worthless.
- Sponsor has invested $5,864,810 total ($25,000 for Class B shares and $5,839,810 for private placement units).
- Approximately $1,028,441 in loans, fees, and expenses owed to Sponsor and officers/directors awaiting reimbursement.
- No director elections, executive compensation, or shareholder proposals are on the ballot.
Financial Impact
Trust account of ~$206.3M; redemption price ~$10.75/share; Sponsor's implied market value of shares ~$58M at $10.78 close; warrants expire worthless if liquidated.
Risk Factors
- Extension may not pass if public shareholders vote against or fail to vote, forcing liquidation.
- Even if extension passes, OACC may still fail to find a business combination by the extended deadline.
- Mass redemptions could significantly reduce trust account cash, making a deal harder to complete.
- CFIUS or other regulatory reviews could delay or block a potential business combination.
- Sponsor's foreign ties may limit the pool of available targets.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-412601 |
| Document: 0001193125-26-412601-index-headers.html | 0001193125-26-412601 |
| Document: 0001193125-26-412601-index.html | 0001193125-26-412601 |
| Document: 0001193125-26-412601.txt | 0001193125-26-412601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $10.71 | awaiting T+1 | — | $10.68 (+0.28%) |
Oct 16, 2026 10d ago | DEFA14A | $10.70 $10.65 | ▲ +0.47% | ▲ +0.89% | $10.68 (+0.19%) |
Oct 16, 2026 10d ago | 8-K | $10.70 $10.65 | ▲ +0.47% | ▲ +0.89% | $10.68 (+0.19%) |
Oct 15, 2026 11d ago | DEFA14A | $10.65 $10.70 | ▼ −0.47% | ▼ −1.58% | $10.68 (−0.28%) |
Oct 15, 2026 11d ago | 8-K | $10.65 $10.70 | ▼ −0.47% | ▼ −1.58% | $10.68 (−0.28%) |
Oct 2, 2026 24d ago | DEF 14A | $10.76 $10.76 | · 0.00% | ▼ −0.55% | $10.68 (−0.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers